Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025

Immunovant initiated with neutral view at Truist, here's why

IMMUNOVANT INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Immunovant, Inc. - IMVT

Patient Recruitment Strategies: Empowering Patients Through Accessible Information, Upcoming Webinar Hosted by Xtalks

Director, GCP Auditing Lead

Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. The role is vital for ensuring the company's clinical studies and operations are compliant with regulatory and quality standards, focusing on planning and executing the GCP audit program.

Sign up with Google

Sign in with Google